Loss of heterozygosity in malignant melanoma at loci on chromosomes 11 and 17 implicated in the pathogenesis of other cancers

I. P M Tomlinson*, A. J. Gammack, J. E. Stickland, G. J. Mann, R. M. Mackie, R. F. Kefford, J. O D McGee

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

62 Citations (Scopus)

Abstract

Forty‐six cases of sporadic melanoma have been investigated for loss of heterozygosity at 4 loci: D11S29 (11q23), YNZ22 (17p13.3), TP53 (17p13.1); and NM23 (17q22). Each of the loci is thought to be important in the pathogenesis of other tumours. Mutations were found infrequently at the YNZ22, NM23, and TP53 loci. At D11S29, however, the frequency of mutation in the melanoma samples was high (67%) and mutations at this locus were associated with younger age at presentation. This region of chromosome 11 is also commonly mutated in breast cancers and haematological malignancies. Genetic aberrations at D11S29 may therefore represent nonspecific mutations found in several malignancies or part of a pathway common to the malignant phenotype. © 1993 Wiley‐Liss, Inc.

Original languageEnglish
Pages (from-to)169-172
Number of pages4
JournalGenes, Chromosomes and Cancer
Volume7
Issue number3
DOIs
Publication statusPublished - 1993
Externally publishedYes

Fingerprint

Dive into the research topics of 'Loss of heterozygosity in malignant melanoma at loci on chromosomes 11 and 17 implicated in the pathogenesis of other cancers'. Together they form a unique fingerprint.

Cite this